Key points from this report:
- Buy PerkinElmer (PKI). The stock is actionable after breaking out from a seven-week flat base in heavy volume. Add to positions.
- PerkinElmer has a top three market position in 65–70% of its product lines. Driven by increasing diagnostic revenue, recurring revenue now accounts for 75% of total revenue, up from 55% in 2014.
- The company is now the global leader in biochemical prenatal testing, newborn screening, and global autoimmune in vitro diagnostics. Through this improving product mix as well as geographic expansion, the company has tripled its TAM to ~$50B.